Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

March 23, 2021

Study Completion Date

April 30, 2021

Conditions
Huntington Disease
Interventions
BIOLOGICAL

Cellavita HD lower dose

The participants will receive a total of 9 intravenous administrations of 1x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).

BIOLOGICAL

Cellavita HD higher dose

The participants will receive a total of 9 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).

OTHER

Placebo

The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).

Trial Locations (1)

13271-130

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos

All Listed Sponsors
collaborator

Cellavita Pesquisa Científica Ltda

OTHER

lead

Azidus Brasil

INDUSTRY

NCT03252535 - Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease | Biotech Hunter | Biotech Hunter